Target Name: CD63
NCBI ID: G967
Review Report on CD63 Target / Biomarker Content of Review Report on CD63 Target / Biomarker
CD63
Other Name(s): Limp1 | Melanoma-associated antigen MLA1 | lysosomal-associated membrane protein 3 | tetraspanin-30 | Lysosome integral membrane protein 1 | Lysosome-associated membrane glycoprotein 3 | melanoma-associated antigen MLA1 | MLA1 | Lysosomal-associated membrane protein 3 | TSPAN30 | Granulophysin | Melanoma-associated antigen ME491 | CD63 antigen | Ocular melanoma-associated antigen | OMA81H | Tetraspanin-30 | limp1 | lysosome-associated membrane glycoprotein 3 | LAMP-3 | ocular melanoma-associated antigen | Tspan-30 | CD63 antigen (melanoma 1 antigen) | CD63 antigen (isoform A) | melanoma-associated antigen ME491 | tspan-30 | CD63 molecule | lysosome integral membrane protein 1 | CD63 molecule, transcript variant 1 | CD63_HUMAN | CD63 variant 1 | Melanoma 1 antigen | ME491 | granulophysin

CD63 (Limp1) as a Drug Target and Biomarker: Implications for Cancer Treatment

Cancer is a leading cause of morbidity and mortality worldwide, affecting millions of individuals worldwide. The development and progression of cancer are guided by various factors, including genetic mutations, epigenetic alterations, and signaling pathways. CD63 (Cytosine DNA Terminal 63), a non-coding RNA molecule, has been identified as a potential drug target and biomarker in various cancer types. In this article, we will explore the biology of CD63, its potential as a drug target, and its potential as a biomarker for cancer diagnosis and treatment.

CD63: A Non-Code RNA Molecule and Its Functions

CD63 is a non-coding RNA molecule that plays a critical role in various cellular processes. It is expressed in most tissues and cells, and its levels are regulated by various factors, including DNA replication, cellular stress, and cell cycle progression. CD63 is composed of 194 amino acid residues and has a molecular weight of 21 kDa. It is localized to the nuclear perimulus, where it is involved in the regulation of DNA replication and cell cycle progression.

CD63 functions as a transcription factor, playing a role in the regulation of various gene expression pathways. It has been shown to play a role in the regulation of cell cycle progression, where it promotes the G1 phase and the G2/M phase of the cell cycle. CD63 has also been shown to play a role in the regulation of DNA replication, where it promotes DNA replication in the S phase and protects the cell from DNA damage.

CD63 as a Potential Drug Target

CD63 has been identified as a potential drug target due to its unique biology and various cellular processes. One of the main reasons for its potential as a drug target is its involvement in the regulation of cell cycle progression, which is a critical process for the development and progression of cancer. Therefore, inhibitors that can disrupt CD63's function in cell cycle progression could be effective in treating various types of cancer.

Another potential mechanism by which CD63 can be targeted is its role in the regulation of DNA replication. CD63 has been shown to promote DNA replication in the S phase, which is a critical step in the replication of cancer cells. Therefore, inhibitors that can disrupt CD63's function in DNA replication could be effective in treating cancer cells that are sensitive to DNA replication inhibitors.

In addition to its role in cell cycle progression and DNA replication, CD63 has also been shown to play a role in the regulation of cellular stress and inflammation. Therefore, inhibitors that can disrupt CD63's function in these processes could also be effective in treating various types of cancer.

CD63 as a Potential Biomarker

CD63 has also been identified as a potential biomarker for cancer diagnosis and treatment. The expression of CD63 has been shown to be altered in various types of cancer, including breast, lung, and ovarian cancer. Therefore, the levels of CD63 can be used as a biomarker for cancer diagnosis and treatment.

CD63 has also been shown to play a role in the regulation of cellular stress and inflammation, which are important factors in the development and progression of cancer. Therefore, the levels of CD63 can also be used as a biomarker for monitoring the effectiveness of cancer treatments.

Conclusion

In conclusion, CD63 is a non-code RNA molecule that plays a critical role in various cellular processes. Its functions include regulation of cell cycle progression, DNA replication, and cellular stress and inflammation. As a potential drug target and biomarker, CD63 has the potential to be used in the treatment of various types of cancer. Further research is needed to fully understand its biology and develop effective treatments.

Protein Name: CD63 Molecule

Functions: Functions as cell surface receptor for TIMP1 and plays a role in the activation of cellular signaling cascades. Plays a role in the activation of ITGB1 and integrin signaling, leading to the activation of AKT, FAK/PTK2 and MAP kinases. Promotes cell survival, reorganization of the actin cytoskeleton, cell adhesion, spreading and migration, via its role in the activation of AKT and FAK/PTK2. Plays a role in VEGFA signaling via its role in regulating the internalization of KDR/VEGFR2. Plays a role in intracellular vesicular transport processes, and is required for normal trafficking of the PMEL luminal domain that is essential for the development and maturation of melanocytes. Plays a role in the adhesion of leukocytes onto endothelial cells via its role in the regulation of SELP trafficking. May play a role in mast cell degranulation in response to Ms4a2/FceRI stimulation, but not in mast cell degranulation in response to other stimuli

The "CD63 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD63 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9